Thymosin alpha-1.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacology and early clinical trials
PubMed 11381492 · doi:10.1093/ajhp/58.10.886
What was done
This paper reviewed the pharmacology, pharmacokinetics, adverse effects, dosing, and clinical trial efficacy of thymosin alpha-1 (TA1), a synthetic immunomodulating polypeptide. The review synthesized results from four clinical trials evaluating TA1 for chronic hepatitis B (total n=195) and three clinical trials for chronic hepatitis C (total n=162).
What was found
TA1 is rapidly absorbed with peak serum concentrations within 2 hours, a half-life of approximately 2 hours, and a return to baseline within 24 hours. For hepatitis B: one study reported 6-month HBV DNA clearance in 9 of 17 TA1 patients versus 10 of 16 receiving interferon alfa-2b (IFN-alpha 2b) and 4 of 15 historical controls; an open-label trial observed 53% clearance at 6 months; and a randomized controlled trial reported 40.6% and 25.6% clearance after 6 and 12 months of TA1, respectively, versus 9.4% in untreated controls. For hepatitis C: TA1 monotherapy did not significantly differ from placebo for ALT normalization; combination TA1 plus IFN-alpha 2b yielded higher 6-month ALT normalization (71% vs 35%) and HCV RNA clearance (65% vs 29%) compared to IFN-alpha 2b alone in one trial; and another trial showed 6-month ALT normalization in 37.1% (combination), 16.2% (IFN-alpha 2b alone), and 2.7% (placebo). Adverse events were generally limited to local irritation at the injection site.
Why it matters
The review summarizes early evidence for TA1 as a potential monotherapy in hepatitis B or an adjuvant with IFN-alpha 2b in hepatitis C. It outlines standard subcutaneous dosing (1.6 mg twice weekly) while noting unproven effects on long-term clinical endpoints.
Limits
The publication is a non-systematic narrative review. The underlying trials featured small sample sizes, heterogeneous methodologies (including historical controls and open-label designs), mixed efficacy findings, and no assessment of long-term morbidity or mortality.
Cited by
- contradicts Thymosin alpha-1 was previously FDA-approved under the brand name Zadaxin for conditions involving thymic abnormalities like DiGeorge syndrome.